Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(3):197; doi:10.1093/jnci/91.3.197
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 3, 197, February 3, 1999
© 1999 Oxford University Press

IN THIS ISSUE

Cervical Dysplasia

How aggressively should physicians treat dysplasia of the uterine cervix? The answer depends on the natural history of the disease—that is, how often different forms of dysplasia return to normal or progress to cancer. Because treatment is now standard for most forms, Holowaty et al. (p. 252) analyzed the progression and regression of dysplasias among women whose Pap smears were analyzed by a large Canadian cytopathologic laboratory during 1970-1980 (an era of more conservative treatment) and linked the cytopathologic data with . . . [Full Text of this Article]

Risk of HPV Infection

BRCA1 and BRCA2 Mutations and Cancer Survival

Estrogen Replacement Therapy and Breast Cancer Survival

Prognostic Indicator for Node-Negative Breast Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?